9results about How to "Clinically convenient" patented technology

The invention discloses an application of isorhamnetin-3-O-neohesperidin in preparation of a medicine for preventing and / or treating benign prostatic hyperplasia. In-vitro experiments show that the isorhamnetin-3-O-neohesperidin can inhibit proliferation of prostatic hyperplasia cells, promote apoptosis of the prostatic hyperplasia cells and regulate inflammatory response of the prostatic hyperplasia cells, and rat experiments show that the isorhamnetin-3-O-neohesperidin can improve the hormone endocrine disorder condition of an animal model body, and can inhibit the prostatic hyperplasia cells and promote the prostatic hyperplasia cell apoptosis and regulate the inflammatory response of the prostatic hyperplasia cells. The anti-inflammatory ability of an animal model is enhanced, and the traditional Chinese medicine composition has a relatively good treatment effect on prostatic hyperplasia caused by testosterone propionate. The medicine for preventing and / or treating benign prostatic hyperplasia, provided by the invention, contains a pharmacodynamic dose of isorhamnetin-3-O-neohesperidin and a pharmaceutically acceptable carrier or auxiliary material, can be prepared into a medicine dosage form which is convenient for clinical use and can play an optimal curative effect, and has a relatively high clinical application value.

An omni-directional wireless energy transmission system for implanted / interventional diagnosis and treatment equipment comprises an omni-directional wireless energy transmitting subsystem which is arranged outside a body and is used for generating an alternating rotating magnetic field with constant intensity and a wireless energy receiving subsystem which wirelessly receives electric energy through electromagnetic induction, wherein the wireless energy receiving subsystem forwards received wireless energy to an internal circuit of the implanted / interventional diagnosis and treatment equipment. A three-dimensional energy transmitting coil and one-dimensional energy receiving coil coupling structure is adopted, a high-order LCC-S resonance compensation topological structure insensitive to load change is adopted, and it can be guaranteed that implantation / interventional diagnosis and treatment equipment can obtain sufficient and stable energy supply at any position and posture in a working space; and the applicability of the wireless energy transmission system is improved.

The present application provides a method for predicting the efficacy of umbilical cord blood natural killer cell treatment of neuroblastoma, belonging to the technical field of medical prediction and evaluation. The present application solves the clinical need for early and accurate prediction of the efficacy of immunotherapy for neuroblastoma. The method comprises: obtaining peripheral blood test data of a neuroblastoma patient before multiple reinfusion treatment nodes of umbilical cord blood natural killer cell treatment; based on the processed node-level peripheral blood test data, at least one dynamic linkage feature reflecting the dynamic linkage relationship of the indicators in the patient's body is calculated; at least one static feature index is obtained; the dynamic linkage feature and the static feature index are input into a pre-trained efficacy prediction model to obtain the response probability of the patient to umbilical cord blood natural killer cell immunotherapy. The present application accurately predicts the efficacy of umbilical cord blood natural killer cell treatment of neuroblastoma by analyzing the peripheral blood test data of the patient at multiple time points and constructing dynamic linkage features.

The application relates to the technical field of oral cavity expansion, in particular to an expansion device for oral cavity treatment, which comprises an expansion forceps, a self-adaptive supporting mechanism and an expansion maintaining assembly. The expansion forceps is opened by applying force to the forceps body, so that the forceps body is in contact with the mouth and the expansion of the mouth is realized. The self-adaptive supporting mechanism is installed on one side of the bottom of the expansion forceps. When the self-adaptive supporting mechanism is pressed, the supporting mechanism can be supported on the cheek area of the mouth. When the expansion forceps is expanded by applying force, the expansion maintaining assembly is locked by a one-way locking structure, so that the expansion forceps cannot be restored due to the force applied by the mouth after being opened. The operation is convenient, and the hands of the doctor are freed. The supporting feet of the self-adaptive supporting mechanism can automatically adhere to the cheek area of the patient and be locked and positioned by gravity self-falling design, so that the doctor does not need to continuously hold and fix. The one-way locking structure of the expansion maintaining assembly is matched, so that the opening state can be stably maintained after expansion without continuously applying a pushing force, the doctor can focus on the treatment operation, and the diagnosis and treatment efficiency is remarkably improved.

The present invention discloses an individual precise transcranial magnetic stimulation system and optimization method, belonging to the technical field of medical auxiliary equipment. The system includes a main control module, an individual head model optimization module, a magnetic field excitation module, a stimulation coil, a magnetic shielding headgear, a parameter monitoring module, a power module, a communication module and an interaction module. The system does not need to change the conventional magnetic stimulation coil design, but integrates magnetic shielding materials with different conductivity, magnetic permeability, structure and thickness into an easy-to-wear headgear, and at the same time combines individual magnetic resonance data to establish a magnetic stimulation simulation headgear. According to the organizational structure and characteristics of the head model of different individuals, the optimization algorithm is used to select the magnetic shielding headgear with appropriate parameters to achieve the preset focusing and induced electric field strength in the target area, and finally achieve individual precise transcranial magnetic stimulation. The present invention effectively improves the focusing of transcranial magnetic stimulation and enhances the convenience and safety of clinical use.

The invention provides injectable composite gel as well as a preparation method and application thereof. The composite gel comprises a gel carrier and active microspheres which are suspended and dispersed in the gel carrier; wherein the gel carrier comprises a methacrylated hyaluronic acid gel, and the methacrylated hyaluronic acid gel is obtained by cross-linking methacrylated hyaluronic acid; the active microspheres comprise polylactic acid microspheres. The composite gel disclosed by the invention is simple in component, does not contain other components such as a chemical cross-linking agent, an auxiliary suspending agent and a surfactant, and has good injectability and heat resistance, and after moist heat sterilization, microspheres are basically maintained to be spherical, have an excellent dispersion effect in a gel carrier, do not have the conditions of deformation, precipitation and the like, and can be kept stable for a long time without sedimentation.

The present invention belongs to the field of stem cell technology and relates to a kit for efficiently preparing umbilical cord mesenchymal stem cells. The kit comprises umbilical cord preservation solution, umbilical cord washing solution, umbilical cord decomposition solution, cell washing solution, cell culture solution, cell digestion solution, and cell freezing solution. The kit of the present invention can efficiently prepare umbilical cord mesenchymal stem cells, obtain a large number of umbilical cord mesenchymal stem cells in a relatively short time, and is convenient for clinical use.

The invention belongs to the technical field of medicines, and particularly relates to application of a solubilizer in a levornidazole derivative fat emulsion injection, and the solubilizer is selected from one or more of isopropyl myristate or isopropyl palmitate. The L-ornidazole derivative fat emulsion injection with higher safety and better stability is obtained by applying a solubilizer in the L-ornidazole derivative fat emulsion injection, irritation generated during injection can be reduced, terminal sterilization can be realized, the safety risk of a sample is greatly reduced, the drug loading capacity is also greatly increased, and the injection quality of the L-ornidazole derivative fat emulsion injection is improved. And the clinical use is more convenient.

The invention relates to the technical field of medicines, in particular to a pharmaceutical composition of a paclitaxel conjugate, which comprises paclitaxel, a paclitaxel analogue or a conjugate thereof, an organic solvent; a solubilizer; and, a pH regulator. The conjugate is ANG1005, the solubilizer comprises mPEG-DSPE, in the mPEG-DSPE, the molecular weight of PEG is 500-10000, the molecular weight of PEG is 500-10000, and in the mPEG-DSPE, the molecular weight of PEG is 500-1000. The weight ratio of the mPEG-DSPE to the ANG1005 is (3 to 15): 1. According to the preparation method, the active substance solution and the solubilizer solution are prepared respectively, and then the two solutions are mixed together, so that the prepared solution is good in physical stability. When the ANG1005 freeze-drying agent prepared by the invention is redissolved, only normal saline is needed as a redissolving agent, the clarification of the redissolving solution can be realized within 5 minutes, and the clinical use is more convenient; the osmotic pressure of the freeze-drying agent after redissolution is lower than that of an ANG1005 freeze-drying agent in the prior art; meanwhile, in the in-vivo metabolism process of the freeze-drying agent (redissolving solution), ANG1005 is higher in chemical stability and not prone to hydrolysis, paclitaxel released in blood is less, and side effects on the human body are smaller.